Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated levels of C-reactive protein (CRP) are associated with increased risks of ischemic heart disease and ischemic cerebrovascular disease. We tested whether this is a causal association. METHODS: We studied 10,276 persons from a general population cohort, including 1786 in whom ischemic heart disease developed and 741 in whom ischemic cerebrovascular disease developed. We examined another 31,992 persons from a cross-sectional general population study, of whom 2521 had ischemic heart disease and 1483 had ischemic cerebrovascular disease. Finally, we compared 2238 patients with ischemic heart disease with 4474 control subjects and 612 patients with ischemic cerebrovascular disease with 1224 control subjects. We measured levels of high-sensitivity CRP and conducted genotyping for four CRP polymorphisms and two apolipoprotein E polymorphisms. RESULTS: The risk of ischemic heart disease and ischemic cerebrovascular disease was increased by a factor of 1.6 and 1.3, respectively, in persons who had CRP levels above 3 mg per liter, as compared with persons who had CRP levels below 1 mg per liter. Genotype combinations of the four CRP polymorphisms were associated with an increase in CRP levels of up to 64%, resulting in a theoretically predicted increased risk of up to 32% for ischemic heart disease and up to 25% for ischemic cerebrovascular disease. However, these genotype combinations were not associated with an increased risk of ischemic vascular disease. In contrast, apolipoprotein E genotypes were associated with both elevated cholesterol levels and an increased risk of ischemic heart disease. CONCLUSIONS: Polymorphisms in the CRP gene are associated with marked increases in CRP levels and thus with a theoretically predicted increase in the risk of ischemic vascular disease. However, these polymorphisms are not in themselves associated with an increased risk of ischemic vascular disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional biomarkers, including apo B, lipoprotein(a), high-sensitivity C-reactive protein (CRP), coronary artery calcification score, and ankle-brachial index, are independent risk factors associated with increased risk of ASCVD events and may be helpful when the lipid management goal is unclear.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [284]
In the citing paper
“The value of hsCRP as a CV risk factor appears similar to that of conventional CV risk factors – hsCRP is not a causal factor for CV disease and serves as a biomarker only [36].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [36]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“Yet, despite the high CV morbidity and mortality risk, PAD patients are usually inadequately managed compared with CAD patients [511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationFasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Mendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Cited by
Items 701–800 of 840
Índice predictivo para la cardiopatía hipertensiva
Aliaga, A. Á., Aguilera, J. C. G., Vázquez, A. J. Q., Vázquez, Q., Frómeta, A., Cisneros, L., Sánchez, Rosario, L., Gómez, M. G., & de Céspedes, C. M. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Metabolic Aspects of Hepatitis C Virus Infection
Huang, J., Yu, M., Dai, C., Chuang, W., & Chang, W. (2012) · InTech eBooks · doi:10.5772/32494 · Cited by 1
Lipids, foods, and their supplements on cardiovascular health. II. Vegetal sources
Chacín, J. F., Malavé, A., Natera, M. G., & Tovar, M. N. (2009) · Revista Científica UDO Agrícola · Cited by 1
The evaporation of positive genetic association findings. When time has come to go
Kronenberg, F., & Lamina, C. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.07.049 · Cited by 1
Ekblom, K., Marklund, S. L., Jansson, J., Osterman, P., Hallmans, G., Weinehall, L., & Hultdin, J. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.110.958603 · Cited by 1
Markers of Inflammation among Nigerian Periodontitis Patients
Adegoke, O. M. A. A. (2014) · Journal of Immunological Techniques in Infectious Diseases · doi:10.4172/2329-9541.1000127 · Cited by 1
“Recent findings show that patient with elevated levels of CRP have a higher risk of developing atherosclerosis and other cardiovascular diseases; CRP has been proven to exacerbate ischemic necrosis in a complement dependent fashion [14], and a bystander in atherogenesis [15].”
BackgroundRelation between maternal C–reactive protein in early pregnancy and neonatal complications
Hassan, H. Y., Almallh, S. Y., & Effat, D. (2020) · The Scientific Journal of Al-Azhar Medical Faculty Girls · doi:10.4103/sjamf.sjamf_100_20 · Cited by 1
Amezcua-Guerra, B., Amezcua-Castillo, L. M., Guerra-López, J. A., Díaz-Domínguez, K. A., González‐Pacheco, H., & Amezcua-Guerra, L. M. (2024) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2024.0163 · Cited by 1
Pentraxin 3 (PTX3): Possible Role in Critical Care Medicine
Mauri, T., Bottazzi, B., & Pesenti, A. M. (2011) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-642-18081-1_49 · Cited by 1
Genetic Epidemiology of Atherosclerotic Vascular Disease
O’Donnell, C. J., & Fu, Y. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_47 · Cited by 1
C‐Reactive Protein and its Pathophysiological Roles in Atherosclerosis
Fan, J., Zhang, J., & Chen, Y. E. (2015) · Atherosclerosis · doi:10.1002/9781118828533.ch20 · Cited by 3
Genetics of Coronary Heart Disease
Cunnington, M. S., & Keavney, B. D. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch21 · Cited by 1
Inflammatory Biomarkers in Ischemic Heart Disease
Bjerre, M. (2012) · InTech eBooks · doi:10.5772/33905 · Cited by 1
Cardio-Renal Connection: The Role of Hypoxia and Oxidative Stress
Willam, C., Ditting, T., Veelken, R. A., & Jacobi, J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-857-7_26 · Cited by 1
Innate immunity markers in culprit plaques of acute myocardial infarction or stable angina
Lee, C. W., Hwang, I., Park, C.-S., Lee, H., Park, D., Kang, S.-J., Lee, S., Kim, Y., Park, S., & Park, S.-J. (2012) · Biomarkers · doi:10.3109/1354750x.2011.651158 · Cited by 1
Hypertension and C-reactive protein
Hage, F. G. (2012) · Hypertension Research · doi:10.1038/hr.2012.126 · Cited by 1
Sgueglia, G. A., & Crea, F. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32834102ab · Cited by 1
C-reactive protein and vascular risk: From March to Jupiter
Angelantonio, E. D., & Cohen, A. A. (2010) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2010.03.001 · Cited by 1
Inhibiting C-Reactive Protein Synthesis by Cardiac Glycosides in Humans
Torzewski, J., Graf, M., Weber, K., Zaczkiewicz, M., Leier, M., Fröhlich, M., & Zimmermann, O. (2016) · The Open Conference Proceedings Journal · doi:10.2174/2210289201607010007 · Cited by 1
Melichar, B., Hyšpler, R., Kalábová, H., Holečková, P., & Študentová, H. (2012) · Pteridines · doi:10.1515/pteridines.2012.23.1.8 · Cited by 1
Brandt, E. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_30 · Cited by 1
The Role of Biomarkers in Chest Pain Evaluation
Christianson, R., & Meadors, Q. (2022) · Contemporary cardiology · doi:10.1007/978-3-031-05520-1_8 · Cited by 1
Inflammation in heart failure: causal determinant or bystander?
Georgiopoulos, G. A., Delialis, D., & Aimo, A. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001396 · Cited by 1
Wennberg, P. (2009) · DiVA at Umeå University (Umeå University) · Cited by 2
Marcadores genéticos en la enfermedad cardiovascular
Soca, P. E. M. (2014) · Archivos de cardiología de México · doi:10.1016/j.acmx.2013.08.004 · Cited by 1
Goldschmidt‐Clermont, P. J. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2381 · Cited by 1
Leite, W. F. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2014.tde-26022015-152337 · Cited by 1
Biomarkers in Ischemic Heart Disease
Neumann, F., & Schnabel, R. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.10941-x · Cited by 1
Cigarette smoking increases coffee consumption: findings from a Mendelian randomisation analysisPreprint
Bjørngaard, J. H., Nordestgaard, A. T., Taylor, A. E., Treur, J. L., Gabrielsen, M. E., Munafo, M. R., Nordestgaard, B. G., Åsvold, B. O., Romundstad, P., & Smith, G. D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/107037 · Cited by 1
Self-citationGenetics of chronic kidney disease and stroke
Jickling, G. C. (2020) · Neurology · doi:10.1212/wnl.0000000000009631 · Cited by 1
“Mendelian randomization has demonstrated genetic relationships in several diseases such as the role of LpPLA2 in aortic stenosis(4) or a lack of a genetic role for C-reactive protein and high-density lipoprotein as causal factors in myocardial infarction.(5,6) These studies have important implications.”
BackgroundVitamin C and primary prevention of cardiovascular disease: the case for Mendelian randomization
Santos, R. D. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab089 · Cited by 1
Luo, J. M., Thomassen, J. Q., Hegazy, S. H., Rasmussen, I. J., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12688 · Cited by 1
Self-citationO Papel dos Polimorfismos Genéticos na Doença Cardíaca Isquémica
Sá, A. C. M. E. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/pa2d-5870 · Cited by 3
CRP, Uric Acid, and Other Novel Factors in the Pathogenesis of Hypertension
Feig, D. I. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-824-9_5 · Cited by 1
“disease. Among a cohort of 50,000 adults with and without history of ischemic CV disease, persons with CRP >3 mg/L had a 1.6-fold increase in relative risk of CV events as compared to those with levels 33 ).”
BackgroundInfluentialCardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors
Maki, K. C., & Rubin, M. R. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-963-5_1
“However, a study of polymorphisms associated with increased CRP, but not with inflammation, showed that such polymorphisms were not themselves associated with increased ischemic CVD risk ( 13 ).”
BackgroundNovel epidemiologic and mechanistic aspects of the metabolic syndrome
Sierra‐Johnson, J. (2009) · Figshare
Dynamics of cortisol in depression and anxiety disorders
Veen, G. (2010) · Leiden Repository (Leiden University)
Medical Management of Carotid Artery Disease
Samson, R. H. (2012) · Wiley eBooks · doi:10.1002/9781118481370.ch30
Blood markers for the diagnosis and prognosis of stroke
Whiteley, W. N. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Jalloun, R. A. (2015) · Digital Commons - USU (Utah State University) · doi:10.26076/4558-0376
Johansen, C. T., MacDonald, A., & Hegele, R. A. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0025307
¿Son necesarios los biomarcadores para la detección de pacientes de riesgo?
Tartaglione, J. E. (2025) · Revista Argentina de Cardiología · doi:10.7775/rac.v77i3.2211
[Other observations regarding the Jupiter study].
Menéndez-Conde, M. (2011) · PubMed
Fang, S., Wang, Y., Amos, C. I., & Lee, J. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2133
Assessment of total cardiovascular risk in hypertensive subjects
Korhonen, P. E. (2009) · UTUPub (University of Turku) · Cited by 5
La CRP, marqueur de la maladie vasculaire ischémique
Marais, O. (2009) · Option/Bio · doi:10.1016/s0992-5945(09)70010-8
Amarenco, P. (2009) · International Journal of Stroke · doi:10.1111/j.1747-4949.2009.00284.x
Novel Biomarkers of Cardiovascular Disease
Welch, T. S. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4288-1_3
Splice site mutations in mismatch repair genes and risk of cancer in the general population
Thomsen, M., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Bojesen, S. E. (2013) · Familial Cancer · doi:10.1007/s10689-013-9601-7
Self-citationOptimizing lipid-lowering therapy in the prevention of coronary heart disease
Packard, C. J. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.51
Nakajima, K., & Saito, M. (2010) · Circulation · doi:10.1161/circulationaha.109.934620
Koike, T., Yu, Y., Zhang, J., Fan, J., Ozaki, Y., Kitajima, S., Nishijima, K., Morimoto, M., Watanabe, T., Bhakdi, S., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.951798
Inflammation and lifestyle in cardiovascular medicine
Andersson, J. S. O. (2010) · DiVA at Umeå University (Umeå University)
Die JUPITER-Studie: Primärprävention bei erhöhtem C-reaktivem Protein
Graf, K. (2009) · Der Kardiologe · doi:10.1007/s12181-009-0159-4
Musings on genome medicine: cholesterol and coronary artery disease
Nathan, D. G., & Orkin, S. H. (2009) · Genome Medicine · doi:10.1186/gm60
Daniel, L. G. R. (2012) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(12)70366-8 · Cited by 1
Genes and mediators of inflammation and development in osteoarthritis
Bos, S. D. (2010) · Leiden Repository (Leiden University)
HafeziAhmadi, M. R., Nafisi, S., Hosseini, E., Bahrami, A. M., & Ghavam, S. M. (2013)
Early Growth and Cardiovascular Development in Childhood
de Jonge, L. L., Haag, C. D., van den Hooven, E. H., & Taal, H. R. (2013)
Köenig, W., Olivares, R. R. R., & CHILTON, R. J. (2009)
SECTION 2 Organ-Specifi c Function Tests and Drug-Induced Diseases
Lange, R. A., & Hillis, L. D. (2014)
Risk factors, survival and impact of invasive treatment in symptomatic chronic lower limb ischemia
Virkkunen, J. (2010) · Tampere University Institutional Repository (Tampere University)
Neukamm, A. M. C. (2015) · NVA (Nasjonalt vitenarkiv)
Effective Lipid-lowering Therapy in High-risk Patients
Kastelein, J. J. P., Arsenault, B. J., & Tardif, J. (2011) · European Journal of Cardiovascular Medicine · doi:10.5083/ejcm.20424884.211
Shah, S. H., & de Lemos, J. A. (2009)
TEMAS DE ACTUALIDAD EN CARDIOLOGÍA 2009
Bardají, A., Barrabés, J. A., Sanchis, J. M., & Sanchez, P. L. (2016)
C-Reactive Protein and Atherosclerosis: No Case for Causality
Meyer, B. J. (2008) · Journal watch · doi:10.1056/jc200810290000001
Dierkesmann, R., Gillissen, A., Köhnlein, T., Lorenz, J., MAGNUSSEN, H., Morr, H., Pfeifer, R., Schultze‐Werninghaus, G., Steinkamp, G., Taube, C., et al. (2009) · Pneumologie · doi:10.1055/s-0029-1214943
Lladó, L. I. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Angel, K. (2012) · NORA - Norwegian Open Research Archives
Physicians' Warnings for Unfit Drivers and Risk of Road Crashes
Kaptoge, S., Thompson, S. G., & Danesh, J. (2013)
Molecular genetics of atherosclerosis and acute coronary syndromes
Damani, S. B., & Topol, E. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7295-3927-2.10006-5
Identification of the patient at risk: Current role of biomarkers and evolving avenues for research
Pasterkamp, G., Hoefer, I. E., & de Kleijn, D. P. V. (2012) · CRC Press eBooks · doi:10.3109/9781841848549-5
Genetics of Cardiovascular Disease and Its Role in Risk Prediction
Musunuru, K., & Kathiresan, S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1366-4.00004-4
Judkins, C. (2013) · UWA Profiles and Research Repository (UWA) · Cited by 1
Die JUPITER-Studie: Primär- prävention bei erhöhtem C-reaktivem Protein
Medizin-Kardiologie, I. (2009)
Evaluation of C-reactive protein and fibrinogen among Sickle cell disease patients
Johnkennedy, N., Meludu Samuel, C., Dioka, C. E., Ezeugwunne, I. P., Richard, N., & Obi, P. C. (2013)
Sharma, C., & Madhaw, G. (2017) · IOSR Journal of Dental and Medical Sciences · doi:10.9790/0853-1604034550
Laks, R., Araújo, L. M. Q., de Mello, C., Filho, A., & Cendoroglo, M. S. (2011) · Cited by 5
STUDY ON C-REACTIVE PROTEIN IN CASES OF PRE-ECLAMPSIA
Sinha, C., Sinha, R. B., & Kiran, C. (2017) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2017/1059
Inflammation, platelet aggregation and prognosis in acute myocardial infarction
Modica, A. (2010) · DiVA at Umeå University (Umeå University)
OBSOLETE: Biomarkers in Ischemic Heart Disease
Schnabel, R. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.10941-9
C-Reactive Protein and Cardiovascular Disease in Psoriasis
Goldminz, A. M., & Gottlieb, A. B. (2011) · Psoriasis Forum · doi:10.1177/247553031117a00103
The Role of Cardiovascular Disease in the Patient with Psoriasis
Patel, R. V. (2011) · Psoriasis Forum · doi:10.1177/247553031117a00105
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial
de Tena, J. G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61227-7
SUBCLINICAL CARDIAC DAMAGE IN CARDIOPULMONARY POLYMORBIDITY
Ащеулова, Т. В., Амбросова, Т. М., Kochubiei, O., Honchar, O., & Sytina, I. V. (2019) · Inter Collegas · doi:10.35339/ic.6.2.68-76
Sabek, J. (2019) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/124821
C-reactive protein and chronic obstructive pulmonary disease
Xu, W., & Wang, H. (2012) · Chinese Journal of Asthma · doi:10.3760/cma.j.issn.1673-436x.2012.016.016
Update on lipids and C-reactive protein in acute and chronic coronary heart disease.
Jones, P. H. (2010) · PubMed
Nonalcoholic fatty liver disease in relation to cardiovascular disease: Is all fat equal?
Simons, N. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20210226ns
Melfa, L., Rocca, C., Comai, G., Manna, G. L., & Scarpioni, R. (2021) · Frontiers in Medical Case Reports · doi:10.47746/fmcr.2021.2309
Ong, A. M. (2020) · eScholarship@McGill (McGill) · doi:10.82308/54884
Cardiovascular Impact of Metabolic Abnormalities
Tsiligiannis, S., & Stevenson, J. C. (2021) · ISGE series · doi:10.1007/978-3-030-63650-0_17
(2018) · Wiley eBooks · doi:10.1002/9781118829875.refs
Metadata
- Authors
- Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Rigshospitalet (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-30
- Volume
- 359
- Issue
- 18
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081615427
- Cited by
- 839
- References
- 36
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 21 · 2023: 21 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 25 · 2018: 28 · 2017: 40 · 2016: 48 · 2015: 44 · 2014: 61 · 2013: 56 · 2012: 76
- FWCI
- 102.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- C-reactive protein, ischemic heart disease, ischemic cerebrovascular disease, ischemic vascular disease, CRP gene polymorphisms, apolipoprotein E, high-sensitivity CRP, genetic association, cholesterol levels, causal relationship
- MeSH terms
- C-Reactive Protein, Cerebrovascular Disorders, Cross-Sectional Studies, Female, Humans, Male, Polymorphism, Genetic, Risk Factors, Cohort Studies, Biomarkers, Myocardial Ischemia, Genetic Predisposition to Disease, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.